货号 | HY524016 |
---|---|
品牌 | abinScience |
种属反应性 | Human |
应用 | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
宿主 | Human |
同种型 | IgG1-kappa |
表达系统 | Mammalian Cells |
种属 | Human |
克隆类型 | Monoclonal |
靶标 | Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10 |
内毒素水平 | Please contact with the lab for this information. |
纯度 | >95% as determined by SDS-PAGE. |
纯化方式 | Protein A/G purified from cell culture supernatant. |
Accession号 | P02778 |
状态 | Liquid |
保存溶液 | 0.01M PBS, pH 7.4. |
稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
别名 | BMS-936557, MDX-1100, 946414-98-8 |
背景 | Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis. • The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616 |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Detects CXCL10/IP-10 in indirect ELISAs.
24小时产品查询
扫一扫关注我们
专属渠道经理